Granulomatosis With Polyangiitis Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Chemocentryx, Amgen, Genentech, Biogen, GlaxoSmithKline, Guangdong Hengrui Pharmaceutical, NS Pharma, Inc., AstraZeneca

DelveInsight's "Granulomatosis With Polyangiitis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Granulomatosis With Polyangiitis, historical and forecasted epidemiology as well as the Granulomatosis With Polyangiitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Granulomatosis With Polyangiitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Granulomatosis With Polyangiitis Market Forecast
https://www.delveinsight.com/sample-request/granulomatosis-with-polyangiitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Granulomatosis With Polyangiitis Market Report:
• The Granulomatosis With Polyangiitis market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In September 2024, AstraZeneca's FASENRA® (benralizumab) has received approval in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare, immune-mediated vasculitis that can cause damage to various organs and, if left untreated, can be life-threatening.
• In 2023, TAVNEOS dominated the granulomatosis with polyangiitis market, reaching an impressive market value of USD 70 million. Additionally, glucocorticosteroids and immunosuppressive therapies accounted for significant portions of the market share.
• The prevalence of granulomatosis with polyangiitis (GPA) in the United States, estimated at 32,000 cases in 2023, is projected to increase by 2034. This growth is attributed to factors such as an aging population, advancements in diagnostic techniques, a rise in autoimmune disorders, and environmental influences.
• In 2023, approximately half of the granulomatosis with polyangiitis (GPA) cases involved the upper and lower respiratory tracts. This is because the disease commonly targets small-to-medium-sized blood vessels in these regions, causing inflammation and granuloma formation. This often leads to conditions such as chronic sinusitis, nasal blockage, and lung nodules.
• In 2023, a substantial number of diagnosed prevalent cases in the United States underwent treatment. However, around 40% of these cases were identified as relapsed or refractory.
• In 2023, the EU4 countries and the UK represented 55% of the total diagnosed prevalent cases of granulomatosis with polyangiitis.
• The US FDA has approved two medications for treating granulomatosis with polyangiitis: TAVNEOS (avacopan), developed by Chemocentryx/Amgen, and RITUXAN (rituximab), developed by Genentech/Biogen.
• Key Granulomatosis With Polyangiitis Companies: Chemocentryx, Amgen, Genentech, Biogen, University of Pennsylvania, Shanghai Zhongshan Hospital, Assistance Publique - Hôpitaux de Paris, GlaxoSmithKline, Guangdong Hengrui Pharmaceutical, NS Pharma, Inc., AstraZeneca, Essen Biotech, Novartis, Alpine Immune Sciences, Inc., and others
• Key Granulomatosis With Polyangiitis Therapies: TAVNEOS (avacopan), RITUXAN (rituximab), Trimethoprim Sulfamethoxazole, Tofacitinib, Mepolizumab, Depemokimab, SHR-1703, NS-229, Benralizumab, CD19- BCMA CAR-T cells, Iptacopan, povetacicept, and others
• The Granulomatosis With Polyangiitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Granulomatosis With Polyangiitis pipeline products will significantly revolutionize the Granulomatosis With Polyangiitis market dynamics.

Granulomatosis With Polyangiitis Overview
Granulomatosis with Polyangiitis (GPA), formerly known as Wegener's granulomatosis, is a rare autoimmune disease characterized by inflammation of the blood vessels (vasculitis), which can restrict blood flow to various organs. This inflammation leads to the formation of granulomas, which are small areas of inflammation that can affect multiple organ systems, particularly the respiratory tract and kidneys.

Get a Free sample for the Granulomatosis With Polyangiitis Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/granulomatosis-with-polyangiitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Granulomatosis With Polyangiitis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Granulomatosis With Polyangiitis Epidemiology Segmentation:
The Granulomatosis With Polyangiitis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Granulomatosis With Polyangiitis
• Prevalent Cases of Granulomatosis With Polyangiitis by severity
• Gender-specific Prevalence of Granulomatosis With Polyangiitis
• Diagnosed Cases of Episodic and Chronic Granulomatosis With Polyangiitis

Download the report to understand which factors are driving Granulomatosis With Polyangiitis epidemiology trends @ Granulomatosis With Polyangiitis Epidemiology Forecast
https://www.delveinsight.com/sample-request/granulomatosis-with-polyangiitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Granulomatosis With Polyangiitis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Granulomatosis With Polyangiitis market or expected to get launched during the study period. The analysis covers Granulomatosis With Polyangiitis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Granulomatosis With Polyangiitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Granulomatosis With Polyangiitis Therapies and Key Companies
• TAVNEOS (avacopan): Chemocentryx/Amgen
• RITUXAN (rituximab): Genentech/Biogen
• Trimethoprim Sulfamethoxazole: University of Pennsylvania
• Tofacitinib: Shanghai Zhongshan Hospital
• Mepolizumab: Assistance Publique - Hôpitaux de Paris
• Depemokimab: GlaxoSmithKline
• SHR-1703: Guangdong Hengrui Pharmaceutical
• NS-229: NS Pharma, Inc.
• Benralizumab: AstraZeneca
• CD19- BCMA CAR-T cells: Essen Biotech
• Iptacopan: Novartis
• povetacicept Alpine Immune Sciences, Inc.

Discover more about therapies set to grab major Granulomatosis With Polyangiitis market share @ Granulomatosis With Polyangiitis Treatment Landscape
https://www.delveinsight.com/sample-request/granulomatosis-with-polyangiitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Granulomatosis With Polyangiitis Market Strengths
• Patient and renal survival has improved, and treatment is moving toward individualizing care, minimizing severe adverse events, and preventing relapse.
• Prompt diagnosis and aggressive treatment are associated with dramatically improved outcomes, with remission occurring in 60─90% of patients and 2-year survival rates exceeding 90%.

Granulomatosis With Polyangiitis Market Opportunities
• One of the major opportunities is the new diagnostic tools or methods that can be explored for the early detection of in the affected patient pool.
• Drug combination therapy can be more efficacious and may help reliably and swiftly induce remission while reducing glucocorticoid toxicity.

Scope of the Granulomatosis With Polyangiitis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Granulomatosis With Polyangiitis Companies: Chemocentryx, Amgen, Genentech, Biogen, University of Pennsylvania, Shanghai Zhongshan Hospital, Assistance Publique - Hôpitaux de Paris, GlaxoSmithKline, Guangdong Hengrui Pharmaceutical, NS Pharma, Inc., AstraZeneca, Essen Biotech, Novartis, Alpine Immune Sciences, Inc., and others
• Key Granulomatosis With Polyangiitis Therapies: TAVNEOS (avacopan), RITUXAN (rituximab), Trimethoprim Sulfamethoxazole, Tofacitinib, Mepolizumab, Depemokimab, SHR-1703, NS-229, Benralizumab, CD19- BCMA CAR-T cells, Iptacopan, povetacicept, and others
• Granulomatosis With Polyangiitis Therapeutic Assessment: Granulomatosis With Polyangiitis current marketed and Granulomatosis With Polyangiitis emerging therapies
• Granulomatosis With Polyangiitis Market Dynamics: Granulomatosis With Polyangiitis market drivers and Granulomatosis With Polyangiitis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Granulomatosis With Polyangiitis Unmet Needs, KOL's views, Analyst's views, Granulomatosis With Polyangiitis Market Access and Reimbursement

To know more about Granulomatosis With Polyangiitis companies working in the treatment market, visit @ Granulomatosis With Polyangiitis Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/granulomatosis-with-polyangiitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Granulomatosis With Polyangiitis Market Report Introduction
2. Executive Summary for Granulomatosis With Polyangiitis
3. SWOT analysis of Granulomatosis With Polyangiitis
4. Granulomatosis With Polyangiitis Patient Share (%) Overview at a Glance
5. Granulomatosis With Polyangiitis Market Overview at a Glance
6. Granulomatosis With Polyangiitis Disease Background and Overview
7. Granulomatosis With Polyangiitis Epidemiology and Patient Population
8. Country-Specific Patient Population of Granulomatosis With Polyangiitis
9. Granulomatosis With Polyangiitis Current Treatment and Medical Practices
10. Granulomatosis With Polyangiitis Unmet Needs
11. Granulomatosis With Polyangiitis Emerging Therapies
12. Granulomatosis With Polyangiitis Market Outlook
13. Country-Wise Granulomatosis With Polyangiitis Market Analysis (2020-2034)
14. Granulomatosis With Polyangiitis Market Access and Reimbursement of Therapies
15. Granulomatosis With Polyangiitis Market Drivers
16. Granulomatosis With Polyangiitis Market Barriers
17. Granulomatosis With Polyangiitis Appendix
18. Granulomatosis With Polyangiitis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Granulomatosis With Polyangiitis Pipeline https://www.delveinsight.com/report-store/granulomatosis-with-polyangiitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Granulomatosis With Polyangiitis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Granulomatosis With Polyangiitis market. A detailed picture of the Granulomatosis With Polyangiitis pipeline landscape is provided, which includes the disease overview and Granulomatosis With Polyangiitis treatment guidelines.

Granulomatosis With Polyangiitis Epidemiology https://www.delveinsight.com/report-store/granulomatosis-with-polyangiitis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Granulomatosis With Polyangiitis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Granulomatosis With Polyangiitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight
• Percutaneous Arterial Closure Device Market: https://www.delveinsight.com/report-store/vascular-closure-devices-market
• Transdermal Drug Delivery Devices: https://www.delveinsight.com/report-store/transdermal-drug-delivery-devices-market
• Infusion Pumps Market: https://www.delveinsight.com/report-store/infusion-pumps-market
• Acute Radiation Syndrome Market: https://www.delveinsight.com/report-store/acute-radiation-syndrome-pipeline-insight
• Human Papillomavirus Hpv Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
• Interspinous Spacers Market: https://www.delveinsight.com/report-store/interspinous-spacers-market
• Dengue Fever Market: https://www.delveinsight.com/report-store/dengue-fever-market
• Chronic Hemodialysis Market: https://www.delveinsight.com/report-store/chronic-hemodialysis-market
• Brucellosis Market: https://www.delveinsight.com/report-store/brucellosis-market
• Childhood Atropine For Myopia Progression Market: https://www.delveinsight.com/sample-request/childhood-atropine-for-myopia-progression-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.